挑战不良标签:首次缓解期接受异基因移植的急性髓系白血病患者中ELN 2022不良细胞遗传学亚组的多样结局:来自EBMT ALWP的研究
该EBMT研究纳入1735例2010至2022年间首次缓解期接受异基因造血干细胞移植的ELN 2022不良细胞遗传学成人AML患者,定义11个非重叠不良细胞遗传学组。最常见5组中,单体17或17p异常组及复杂核型涉及单体5、单体7或del(5q)组2年LFS和OS均较差,而其余多数ELN 2022不良类别结局相对较好,提示allo-HSCT可克服其不良结局。
要点
- 单体17或17p异常组2年LFS 22%、OS 25%,结局极差。
- 复杂核型涉及单体5、单体7或del(5q)组2年LFS 27%、OS 37%。
- 无复杂核型的单体5、单体7或del(5q)组2年LFS 55%、OS 63%。
核心结论
- 伴单体17或17p异常或复杂核型涉及单体5、单体7和del(5q)的移植后AML患者结局极差。
- 大多数其他ELN 2022不良类别结局相对较好,包括除5、7和17异常外的伴或不伴单体型核型的复杂核型,提示allo-HSCT可克服其不良结局。
研究设计与样本
- EBMT研究纳入1735例2010至2022年间首次缓解期接受allo-HSCT的ELN 2022不良-risk细胞遗传学成人AML患者。
- 患者中67%为原发AML,中位年龄56岁,定义11个非重叠不良-risk细胞遗传学组。
主要发现
- 第1组(n=394;单体17或abn(17p))2年LFS 22%,OS 25%。
- 第2组(n=313;复杂核型涉及单体5、单体7或del(5q)且无单体17或abn(17p))LFS 27%,OS 37%。
- 第3组(n=201;单体5、单体7或del(5q)无复杂核型且无单体17或abn(17p))LFS 55%,OS 63%。
- 第4组(n=256;复杂核型无单体型核型或不良额外细胞遗传学异常)LFS 50%,OS 61%。
- 第5组(n=213;t(v,11q23)无不良额外细胞遗传学异常)LFS 50%,OS 59%。
关键数值与推荐
- ELN 2022分类中,中危或不良-risk的AML患者在首次缓解期接受allo-HSCT。
- 本研究定义11个非重叠不良-risk细胞遗传学组,其中5个最常见组样本量分别为394、313、201、256和213例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
According to the European LeukemiaNet (ELN) 2022 classification, acute myeloid leukemia (AML) patients with intermediate or adverse risk are offered allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first remission. In this EBMT study, we included 1735 adult AML patients with ELN-2022 adverse-risk cytogenetics allografted between 2010 and 2022 in first remission (67% de novo AML, median age 56 years). Eleven non-overlapping adverse-risk cytogenetics groups were defined. The five most frequent were: Group 1 [n = 394; monosomy 17 or abn(17p); 2-year leukemia-free survival (LFS) 22%, and overall survival (OS) 25%]; Group 2 [n = 313; complex karyotype (CK) involving monosomy 5, monosomy 7, or del(5q) without monosomy 17 or abn(17p); LFS 27%, OS 37%]; Group 3 [n = 201; monosomy 5, monosomy 7, or del(5q) without CK and without monosomy 17 or abn(17p); LFS: 55%, OS: 63%]; Group 4 [n = 256; CK without monosomal karyotype (MK) or adverse additional cytogenetic abnormalities (ACA); LFS 50%, OS 61%]; Group 5 [n = 213; t(v, 11q23) without adverse ACA; LFS 50%, OS 59%]. In multivariable analysis, compared to CK without adverse ACA, LFS was negatively affected by monosomy 17 or 17p abnormalities, monosomy 5, 7, or del(5q) in the presence of CK, and t(8;16). In conclusion, this study revealed a very poor outcome of allografted AML patients with monosomy 17 or 17p abnormalities or CK involving monosomy 5, monosomy 7, and del5q. Outcomes were relatively favorable for most other ELN 2022 adverse categories, including CK with or without MK other than 5, 7, and 17, indicating that allo-HSCT can overcome their poor outcome.
引用
- Bazarbachi A, Galimard JE, Dalle IA, et al. Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP. Am J Hematol. 2025. PMID: 40445901. doi:10.1002/ajh.27726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。